Company intelligence / Profile preview
Kaken Pharmaceutical Co., Ltd.
Bunkyo-ku, Tokyo, Japankaken.co.jp ↗
- Ownership
- Public · 4521
- Employees
- ~1143
- Development stage
- Commercial
01
Overview
Kaken has multiple commercialized products including Artz (anti-osteoarthritis), Clenafin (onychomycosis treatment), Fiblast Spray (wound-healing), Regroth (periodontal regeneration), Adofeed (pain/inflammation relief), Ebrantil (dysuria/hypertension), Procylin (prostaglandin I2 analog), and Mentax (anti-trichophyton)[3][5]
- Therapeutic areas
- CardiovascularRheumatologyNephrologyOphthalmologyImmunologyDermatologyOtherNeurologyInfectious Diseases
- Modalities
- Small moleculesbiologics (recombinant human basic Fibroblast Growth Factor)
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Alumis Inc. (for TYK2 inhibitor ESK-001 development in Japan)
04
Financials
- Market cap
- $895.3M
- Total revenue
- $486M
- Enterprise value
- $554.7M
Beyond the preview
Go deeper on Kaken Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kaken Pharmaceutical Co., Ltd..